Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL) - A Randomised, Placebo Controlled Clinical Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Next Previous
Trial Profile

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL) - A Randomised, Placebo Controlled Clinical Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary) ; Sodium-glucose transport protein inhibitors
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms EXSCEL
  • Sponsors Amylin Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company

Most Recent Events

  • 01 Oct 2024 Results (n=11,101) assessing glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes published in the Diabetes, Obesity and Metabolism.
  • 13 Nov 2023 Results assessing high throughput proteomic profiling performed using the SomaLogic SomaScan platform in 5473 patients with type 2 diabetes enrolled in the EXSCEL clinical trial, presented at the American Heart Association Scientific Sessions 2023.
  • 01 Jun 2023 Results assessing the sex differences in the characteristics and outcomes in participants with type 2 diabetes, with or without cardiovascular disease, published in the Diabetes, Obesity and Metabolism.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top